#United States #New York #Rosen Law Firm #Investment Fraud #Cerevel Therapeutics

Investors Urged to Join Cerevel Therapeutics Class Action

As the deadline for investors approaches, those who have incurred losses exceeding $100,000 on their shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) are being encouraged to join a significant securities fraud class action lawsuit. This update comes from the reputable Rosen Law Firm, a global leader in investor rights, which emphasizes the unique opportunity for affected investors to potentially recover losses without upfront costs.

Understanding the Claim

During the period from October 11, 2023, to August 1, 2024, referred to as the Class Period, investors who either sold their shares or held shares entitled them to vote on the merger between Cerevel and AbbVie Inc. are eligible to participate in this lawsuit. Notably, those who sold their shares at the same time as Bain Capital's strategic acquisition on October 16, 2023, are also among those who might seek compensation.

Rather than bearing the burden of legal costs, investors can opt for a contingency fee arrangement that allows them to join without any out-of-pocket fees. This method ensures that participants only pay legal fees if the case yields a successful recovery.

How to Join the Class Action

To express your interest in becoming part of this legal action, investors can do so by visiting Rosen Law Firm's dedicated page for the lawsuit at rosenlegal.com or contacting Phillip Kim, Esq. directly via the toll-free number 866-767-3653. Additionally, for any inquiries, an email can be sent to info@rosenlegal.com.

The deadline to file as a lead plaintiff is set for June 3, 2025. Being appointed as a lead plaintiff means representing the collective interests of other class members in guiding the litigation process.

Why Choose Rosen Law Firm?

The selection of qualified legal representation is vital in securities litigation. Rosen Law Firm has established itself with a robust track record of successful litigation in securities class actions. Unlike certain firms that merely act as intermediaries, Rosen Law Firm is involved directly in the litigation process, ensuring their clients receive comprehensive support.

The firm has achieved notable success in the past, including the largest securities class action settlement against a Chinese company at the time and has been ranked consistently among top firms for handling securities class action cases. They have also secured hundreds of millions of dollars for investors in previous lawsuits, validating their effectiveness and dedication.

Details of the Securities Fraud Case

The class action alleges that during the Class Period, defendants issued misleading statements related to Cerevel’s secondary stock offering on October 16, 2023, as well as the details provided in its proxy statement on January 18, 2024. It is claimed that this stock offering was strategically designed by major shareholders, notably Bain Capital, LP, and Pfizer Inc., to benefit Bain by enabling them to increase their holdings at significantly reduced prices prior to the acquisition by AbbVie.

This acquisition announcement only 51 days post-offering at a purchase price of $45 per share — almost double the offering price — highlights the controversial nature of this case, as it resulted in Bain receiving financial benefits of more than $120 million. Upon realizing the true nature of the situation, investors are believed to have suffered unforeseen damages.

Current Status and Next Steps

It is important to note that while a class action lawsuit has been initiated, no class has yet been certified. Until certification, affected investors must retain counsel to be represented in court. Those who prefer not to participate actively may remain as absent class members without immediate action.

For updates and further information, investors can follow Rosen Law Firm on various platforms, including LinkedIn, Twitter, and Facebook, or contact them directly using their provided information. Attorney Laurence Rosen, alongside Phillip Kim, leads the firm in advocating for investors' rights and securing their financial interests in this complex situation.

Investors with losses over $100,000 are strongly advised to consider joining this class action, as it could be an important step toward recovering their losses in light of the alleged fraud related to Cerevel Therapeutics.